Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage ...

The CheckMate 73L study found that adding nivolumab to concurrent chemoradiation followed by nivolumab plus ipilimumab did not significantly improve progression-free survival over chemoradiation followed by durvalumab in patients with stage III NSCLC. Median PFS was 16.7 months vs 15.6 months, missing the primary endpoint. Median overall survival was 34.6 months vs 40.2 months. Objective response rates were 68% vs 64%. No new safety signals were observed, but pneumonitis increased with concurrent immunotherapy and chemoradiation.